Conv. Plasma
Nigella Sativa

All remdesivir studies
Meta analysis
study COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 42% Improvement Relative Risk Remdesivir for COVID-19  Raad et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective study in multiple countries (January - November 2020) Lower mortality with remdesivir (p=0.009) Raad et al., medRxiv, August 2022 Favors remdesivir Favors control

International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship

Raad et al., medRxiv, doi:10.1101/2022.08.25.22279181
Aug 2022  
  Source   PDF   All   Meta
Retrospective 3,966 COVID-19 patients, 1,115 with cancer, showing lower mortality with remdesivir and higher mortality with convalescent plasma.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
Study covers convalescent plasma and remdesivir.
risk of death, 42.0% lower, OR 0.58, p = 0.009, adjusted per study, multivariable, day 30, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Raad et al., 26 Aug 2022, retrospective, multiple countries, preprint, 52 authors, study period January 2020 - November 2020. Contact:,
This PaperRemdesivirAll
International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship
Issam Raad, Ray Hachem, Nigo Masayuki, Tarcila Datoguia, Hiba Dagher, Ying Jiang, Vivek Subbiah, Bilal Siddiqui, Arnaud Bayle, Robert Somer, Ana Fernández Cruz, Edward Gorak, Arvinder Bhinder, Nobuyoshi Mori, Nelson Hamerschlak, Samuel Shelanski, Tomislav Dragivich, Yee Elise Vong Kiat, Suha Fakhreddine, Pierre Abi Hanna, Roy F Chemaly, Victor Mulanovich, Javier Adachi, Jovan Borjan, Fareed Khawaja, Bruno Granwehr, Teny John, Eduardo Yepez Guevara, Harrys Torres, Natraj Reddy Ammakkanavar, Marcel Yibirin, Cielito C Reyes-Gibby, Mala Pande, Noman Ali, Raniv Dawey Rojo, Shahnoor M Ali, Rita E Deeba, Patrick Chaftari, Takahiro Matsuo, Kazuhiro Ishikawa, Ryo Hasegawa, Ramón Aguado-Noya, Álvaro García-García, Cristina Traseira Puchol, Dong-Gun Lee, Monica Slavin, Benjamin Teh, Cesar A Arias, Dimitrios P Kontoyiannis, Alexandre E Malek, Anne-Marie Chaftari
Background: In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries. Methods: We retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers. Results: We analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p≤0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03). Conclusions: Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality. .
Albiges, Foulon, Bayle, Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort, Nat Cancer
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of Covid-19 -Final Report
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Chavez-Macgregor, Lei, Zhao, Scheet, Giordano, Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer, JAMA Oncol
Gottlieb, Vaca, Paredes, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med
He, Chen, Chen, COVID-19 in persons with haematological cancers, Leukemia
Janiaud, Axfors, Schmitt, Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis, JAMA
Klassen, Sj, Johnson, Carter, Wiggins et al., The Effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis, Mayo Clinic Proceedings
Kucirka, Lauer, Laeyendecker, Boon, Lessler, Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure, Ann Intern Med
Kuderer, Choueiri, Shah, Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet
Lai, Chen, Wang, Chen, Wang et al., Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials, J Antimicrob Chemother
Lee, Cazier, Angelis, COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study, Lancet
Libster, Marc, Wappner, Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults, N Engl J Med
Liu, Lin, Baine, Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study, Nat Med
Lunski, Burton, Tawagi, Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana
Mahase, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, BMJ
Mehta, Goel, Kabarriti, Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System, Cancer Discov
Mozaffari, Chandak, Zhang, Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort, Clin Infect Dis
Reafc-Twg, Sterne, Murthy, Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, JAMA
Recovery, Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Rezagholizadeh, Khiali, Sarbakhsh, Entezari-Maleki, Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis, Eur J Pharmacol
Rivera, Peters, Panagiotou, Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study, Cancer Discov
Robilotti, Babady, Mead, Determinants of COVID-19 disease severity in patients with cancer, Nat Med
Ruthrich, Giessen-Jung, Borgmann, COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry, Ann Hematol
Salazar, Christensen, Graviss, Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG, Am J Pathol
Shrestha, Budhathoki, Syed, Rawal, Raut et al., Remdesivir: A potential gamechanger or just a myth? A systematic review and meta-analysis, Life Sci
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: A clinicaltherapeutic staging proposal, J Heart Lung Transplant
Siemieniuk, Bartoszko, Ge, Drug treatments for covid-19: living systematic review and network meta-analysis, BMJ
Stc, Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med
Tian, Yuan, Xiao, Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study, Lancet Oncol
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop